

TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/7/2009; page 1 TMP 045

Suggested Formula	Cetirizine Hydrochloride 1 mg/mL Oral Liquid (Solution, 100 mL)	FIN	F 003 714
----------------------	---	-----	-----------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Cetirizine Hydrochloride	0.100	g				
Stevia Powder	0.30	g				
Potassium Sorbate	0.20	g				
Purified Water, USP	90.0	mL	(%)		
Purified Water, USP	q.s. to 100.0	mL	1			
Sodium Hydroxide 10% solution	As required			(C)·		
Hydrochloric Acid 10% solution	As required					

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information						
Hygroscopic (protect from moisture whenever possible): Stevia Powder						
Light Sensitive (protect from li	ght whenever possible): Cetirizine Hydrochloride, Potassium Sorbate					
Suggested Preparatory Guidelines						
Non-Sterile Preparation						
<u>Processing Error /</u> <u>Testing Considerations</u> :	To account for processing error considerations during preparation, it is suggested to measure an additional 5 to 9% of the required quantities of ingredients.					
Special Instruction:	Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.					
	This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.					



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/7/2009; page 2 TMP 045

Suggested	
Buggesieu	
Formula	
гоппина	

Cetirizine Hydrochloride 1 mg/mL Oral Liquid (Solution, 100 mL)

FIN

F 003 714

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Cetirizine Hydrochloride §	0.100	g			
Stevia Powder §	0.30	g			
Potassium Sorbate §	0.20	g	®		
Purified Water, USP	90.0	mL			
Purified Water, USP	q.s. to 100.0	mL			
Sodium Hydroxide 10% solution	As required		1		
Hydrochloric Acid 10% solution	As required				

- § Weigh / measure just prior to use.
- * Takes into account increased batch size conversions and density conversions, if required.

Preparatory Instruction

1. **Powder-liquid preparation:**

- A. Combine and triturate the following ingredients together to form a fine, homogeneous powder blend:
 - -Cetirizine Hydrochloride
 - -Stevia Powder
 - -Potassium Sorbate

2. **Medium preparation:**

A. Incrementally add the fine, homogeneous powder blend (Step 1A) to the Purified Water (90.0 mL *plus* processing error adjustments).

Specifications: Continuously mix until all solid particles have completely dissolved.

End result: Homogeneous liquid-like solution.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/7/2009; page 3

Suggested
Buggesieu
Formula
Formula

Cetirizine Hydrochloride 1 mg/mL Oral Liquid (Solution, 100 mL)

FIN

F 003 714

3. **pH testing:**

- A. Draw an appropriate amount of the mixture (Step 2A).
- B. Test the pH of the sample. It should lie between 4 and 5.
- C. If the pH < 4, carefully add, in a dropwise fashion, the Sodium Hydroxide 10% solution to the mixture:
 - 1. Draw and transfer 1 or 2 drops of the Sodium Hydroxide 10% solution to the mixture.
 - 2. Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 10% solution.
 - 3. Re-test the pH.
 - 4. Continue to add the Sodium Hydroxide 10% solution until the pH of 4 to 5 is obtained.

IMPORTANT: Do not allow the pH to rise above 5.

- D. If the pH > 5, carefully add, in a dropwise fashion, the Hydrochloric Acid 10% solution to the mixture:
 - 1. Draw and transfer 1 or 2 drops of the Hydrochloric Acid 10% solution to the mixture.
 - 2. Stir for at least 5 minutes to evenly disperse the Hydrochloric Acid 10% solution.
 - 3. Re-test the pH.
 - 4. Continue to add the Hydrochloric Acid 10% solution until the pH of 4 to 5 is obtained.

IMPORTANT: Do not allow the pH to fall below 4

4. **Filling to volume:**

A. Add additional Purified Water to the above mixture to fill to the required batch size (100.0 mL *plus* processing error adjustments).

Specifications: Continuously mix.

End result: Homogeneous liquid-like solution.

5. **Product transfer:**

Transfer the final product into the specified dispensing container (see "Packaging requirements").



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/7/2009; page 4

Suggested Formula	Cetirizine Hydrochloride 1 mg/mL Oral Liquid (Solution, 100 mL)	FIN	F 003 714	
----------------------	---	-----	-----------	--

SUGGESTED PRESENTATION

3GESTED PRESENTATION							
Estimate Beyond-Use Da		35 days, refrigerated.	Packaging Requirements		-Tight, light-resistant dispensing bottle -To be administered with metered dose-measuring device.		
	1	Use as directed. Do not exceed dose.	d prescribed	6	Keep refrigerated. Do not freeze.		
	2	Keep out of reach of children.		7	Cap tightly after use.		
Auxiliary	3	Keep in a dry place.		8	Protect from light.		
Labels	4	Do not take with alcohol, tranquilizers or other CNS depre		9	May impair mental and/or physical ability. Use care when operating a car or machinery.		
	5	Consult your health care practition of over-the-comedications are currently being prescribed for future use.	unter	10			
Pharmacist Instructions	Add any applicant labels and sife to the Satistic in anglicute the dispension contains and decreased accesses.						
Patient Instructions	(Contact your pharmacist in the event of adverse reactions						

REFERENCES

1.	Solutions. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition.</i> American Pharmaceutical Association; 2008: 195.
2.	Potassium Sorbate. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 5 th Edition. American Pharmaceutical Association; 2006: 609.
3.	Cetirizine Hydrochloride. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference</i> , 36 th Edition. London, England: The Pharmaceutical Press; 2009: 570.
4.	Cetirizine (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #2022.
5.	Cetirizine. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26th Edition.</i> Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 364.
6.	USP <795>. <i>United States Pharmacopeia XXXI / National Formulary 26.</i> Rockville, MD. US Pharmacopeial Convention, Inc. 2008.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.